EXECUTIVE EMPLOYMENT AGREEMENT BY AND BETWEEN HORIZON THERPEUTICS PLC AND HORIZON THERAPEUTICS USA, INC. AND KARIN ROSENExecutive Employment Agreement • February 24th, 2021 • Horizon Therapeutics Public LTD Co • Pharmaceutical preparations • Illinois
This Executive Employment Agreement (hereinafter referred to as the “Agreement”), is entered into by and between Horizon Therapeutics PLC., an Irish Public Limited Company, and its wholly owned subsidiary, Horizon Therapeutics USA, Inc., a Delaware corporation, each having a principal place of business at 150 S. Saunders Rd, Lake Forest IL 60045, (hereinafter referred to together as the (“Company”) and Karin Rosen (hereinafter referred as to the “Executive”). The terms of this Agreement shall be effective commencing October 30, 2020 (the “Effective Date”).
AMENDED AND RESTATED LICENSE AGREEMENT BETWEEN HORIZON ORPHAN LLC AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA FOR CASE NOS. SD2006-092, SD2017-110, SD2017-113 AND SD2017-236License Agreement • February 24th, 2021 • Horizon Therapeutics Public LTD Co • Pharmaceutical preparations • California
This agreement (“Agreement”) is made by and between Horizon Orphan LLC, as successor in interest to Raptor Pharmaceuticals, Inc. (f/k/a Encode Pharmaceuticals, Inc.), a Delaware limited liability company having an address at 150 South Saunders Road, Lake Forest, Illinois 60045 (“LICENSEE”) and The Regents of the University of California, a California corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 (“UNIVERSITY”), represented by its San Diego campus having an address at University of California, San Diego, Office of Innovation and Commercialization, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 (“UCSD”). This Agreement is being entered into as of the date of last signature below (“Execution Date”) and is deemed effective as of October 31, 2007 (“Effective Date”).
LICENSE AGREEMENTLicense Agreement • February 24th, 2021 • Horizon Therapeutics Public LTD Co • Pharmaceutical preparations • California
THIS LICENSE AGREEMENT is made and entered into as of the 12th day of August 1998, by and among Mountain View Pharmaceuticals, Inc., Duke University, and Bio-Technology General Corporation.
COMMERCIAL SUPPLY AGREEMENTCommercial Supply Agreement • February 24th, 2021 • Horizon Therapeutics Public LTD Co • Pharmaceutical preparations • New Jersey
This Commercial Supply Agreement (this “Agreement”) is entered into as of October 16, 2008, (the “Effective Date”) by and between Enzon Pharmaceuticals, Inc., a Delaware corporation with an address of 685 Route 202-206, Bridgewater, New Jersey 08807 (“Enzon”), and Savient Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at One Tower Center, 14th Floor, East Brunswick, New Jersey 08816 (“Savient”). Enzon and Savient may be referred to individually as a “Party” or collectively as “Parties.”
Manufacturing Services Agreement November 15, 2010Manufacturing Services Agreement • February 24th, 2021 • Horizon Therapeutics Public LTD Co • Pharmaceutical preparations • Ohio
THIS AGREEMENT WITNESSES THAT in consideration of the rights conferred and the obligations assumed herein, and for other good and valuable consideration (the receipt and sufficiency of which are acknowledged by each party), and intending to be legally bound the parties agree as follows:
SUPPLY AGREEMENT Dated: August 3, 2015 between CREALTA Pharmaceuticals LLC and NOF CORPORATIONSupply Agreement • February 24th, 2021 • Horizon Therapeutics Public LTD Co • Pharmaceutical preparations • Delaware
This SUPPLY AGREEMENT (“Agreement”) is made and entered into on the 3rd day of August, 2015 by and between CREALTA Pharmaceuticals LLC., a Delaware limited liability company with offices at 150 S. Saunders Rd., Suite 130, Lake Forest, IL 60045, U.S.A. (“CREALTA”), and NOF CORPORATION, a corporation duly organized under the laws of Japan, located at 20-3, Ebisu 4-chome, Shibuya-ku, Tokyo, 150-6019, Japan (“NOF”),
FIFTH AMENDMENT TO COMMERCIAL SUPPLY AGREEMENTCommercial Supply Agreement • February 24th, 2021 • Horizon Therapeutics Public LTD Co • Pharmaceutical preparations
THIS FIFTH AMENDMENT TO THE AGREEMENT (“Fifth Amendment”) is entered into effective as of this 31st day of August 2016 (“Fifth Amendment Effective Date”) by and between Horizon Pharma Ireland Limited (“HPIL”), an Irish company, and Bio-Technology General (Israel) Ltd., an Israeli company (“BTG” and together collectively with HPIL, “Parties”, and each individually a “Party”).
SECOND AMENDMENT TO THE SUPPLY AGREEMENTSupply Agreement • February 24th, 2021 • Horizon Therapeutics Public LTD Co • Pharmaceutical preparations
THIS SECOND AMENDMENT (“Amendment”) is entered into effective this 22nd day of January 2021, (“Effective Date”) by and between Horizon Therapeutics Ireland DAC, f/k/a Horizon Pharma Ireland Limited (“Horizon”), an Irish company with its principal place of business at and NOF CORPORATION (“NOF”), a Japanese company with its principal place of business at 20-3, Ebisu 4-chome, Shibuya-ku, Tokyo, 150-6019, Japan.
ASSET PURCHASE AGREEMENT between UCYCLYD PHARMA, INC., and HYPERION THERAPEUTICS, INC. dated as of March 22, 2012Asset Purchase Agreement • February 24th, 2021 • Horizon Therapeutics Public LTD Co • Pharmaceutical preparations • Delaware
This Asset Purchase Agreement (this “Agreement”), dated as of March 22, 2012 (the “Signing Date”) is entered into among Ucyclyd Pharma, Inc., a Maryland corporation (“Seller”), Hyperion Therapeutics, Inc., a Delaware corporation (“Buyer”) and solely for the purposes set forth above its signature to this Agreement, Medicis Pharmaceutical Corporation, a Delaware corporation (“Medicis”).
SETTLEMENT AGREEMENT AND FIRST AMENDMENT TO LICENSE AGREEMENTSettlement Agreement and First Amendment to License Agreement • February 24th, 2021 • Horizon Therapeutics Public LTD Co • Pharmaceutical preparations
This Settlement Agreement and First Amendment to the License Agreement (“Settlement Agreement and First Amendment”), effective as of August 21, 2007, is entered into by and among Saul W. Brusilow, M.D., an individual (“Brusilow”) and Brusilow Enterprises, LLC, a Maryland limited liability company (“BEI”) (collectively, the “Licensors”), Ucyclyd Pharma, Inc., a subsidiary of Medicis Pharmaceutical Corporation to which the Agreement has been assigned by Medicis pursuant to Section 11.11 of the Agreement (“Licensee”) and Medicis Pharmaceutical Corporation (“Medicis”).
ASSIGNMENT AND AMENDMENT OF AGREEMENTDevelopment and Manufacturing Services Agreement • February 24th, 2021 • Horizon Therapeutics Public LTD Co • Pharmaceutical preparations
This Assignment of Agreement (the “Assignment”) is entered into on 14 day of February 2018 by and between River Vision Development Corporation, now known as Horizon Pharma Tepro, Inc., and having its principal place of business at 150 South Saunders Road, Lake Forest, IL 60045 (“River Vision”), and CMC Biologics A/S, dba AGC Bilogics, a duly incorporated under the laws of the Kingdom of Denmark (“CMC”), with its principal place of business at Vandtaarnsvej 83B, DK-2860 Soeborg, Copenhagen, Denmark together with its Affiliates (“CMC”), and Horizon Pharma Ireland Limited, an Irish company, with its principal place of business located at Connaught House, 1st Floor, 1 Burlington Road, Dublin D04 C5Y6, Ireland (“Horizon”).
COMMERCIAL SUPPLY AGREEMENTCommercial Supply Agreement • February 24th, 2021 • Horizon Therapeutics Public LTD Co • Pharmaceutical preparations • New York
